A
Amytrx Therapeutics
Biotech & Life Sciences · Nashville, United States · Founded 2014
Advancing a new class of peptide therapies to empower the body's natural intracellular regulatory mechanisms to control inflammation and metabolic disease MoreLess
Amytrx Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel peptide therapies for the treatment of inflammatory and metabolic diseases. The company operates in the biopharmaceutical market, serving clients such as pharmaceutical and biotechnology companies, as well as clinical and research organizations. Amytrx's business model revolves around leveraging its exclusive rights to an extensive portfolio of patents in the US and EU, obtained through a partnership with Vanderbilt University. The company aims to advance new or complementary therapies for chronic diseases characterized by excessive inflammation or metabolic imbalances. Amytrx generates revenue through collaborative opportunities with pharmaceutical and biotechnology partners, as well as through the development and commercialization of its proprietary therapies.
Keywords: peptide therapies, inflammatory diseases, metabolic diseases, biopharmaceutical, clinical-stage, exclusive patents, Vanderbilt University, strategic collaborations, chronic diseases, AMTX 100.
Company overview
Amytrx Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2014
- Headquarters
- Nashville, United States
- Employees
- 2
- Open positions
- None listed
- Dealroom signal
- 58.4
Valuation & funding
Amytrx Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Feb 2024 | $3M | $90M | Undisclosed | — |
| DEBT✓Debt | Feb 2024 | $6M | — | Undisclosed | ↗ |
| SERIES A✓Equity / VC | May 2022 | $18M | $72M | Undisclosed | ↗ |
| SERIES AEquity / VC | Sep 2020 | $11M | $44M | Undisclosed | — |
| SPINOUT✓Other financing | Apr 2014 | $0 | — | Vanderbilt University | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 2 |
| 2025 | 3 |
| 2024 | 3 |
| 2023 | 3 |
| 2022 | 3 |
| 2021 | 4 |
Growth signals
Amytrx Therapeutics website traffic
Latest recorded traffic for Amytrx Therapeutics is 3.3K monthly website visits, up 120% over the last three months. Amytrx Therapeutics's team declined 33.3% over the past year.
Comparisons
Amytrx Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Amytrx Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
2 investors on Amytrx Therapeutics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Amytrx Therapeutics has talent and traffic
team presence
In the news
Latest news about Amytrx Therapeutics
Recent press, funding announcements, and product moves mentioning Amytrx Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Amytrx Therapeutics
An AI-synthesized read of the highest-engagement posts about Amytrx Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Amytrx Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.